All blogsTrust

503A vs 503B Pharmacy: What It Means for Patients

Most peptide prescriptions in the United States are filled by one of two kinds of compounder, and the difference decides who inspects the vial, what may go into it, and whether it was made for you or for a clinic shelf. This page explains sections 503A and 503B in plain language, answers the question people ask AI tools, "is compounded the same as FDA approved," and lists what to ask before you fill a peptide prescription anywhere.

Medically reviewed by Dr. Cory Mellon, MD12 min read

Published October 31, 2026

A 503A pharmacy makes one vial for one named patient. A 503B facility makes batches for clinic shelves. Neither makes an FDA-approved drug.

In this article

Key Takeaways

A 503A pharmacy compounds for one named patient from a valid prescription, under state licensing and USP standards. A 503B outsourcing facility makes larger batches under federal manufacturing rules, mostly for clinics, without a patient-specific prescription.
Neither pathway produces an FDA-approved drug. The FDA does not review a compounded preparation for safety, effectiveness or quality before it is dispensed, whichever section the compounder works under.
Most peptides are not FDA-approved drugs and have no USP monograph, so a 503A pharmacy may compound one only when a lawful basis exists. The FDA moved several peptides through its review in 2026; those are steps in a process, not approvals.
PeRx prescriptions are filled by state-licensed 503A pharmacies with third-party testing of every lot. The vial that arrives was made for you, from a prescription written for you.

503A vs 503B: Quick Facts

503A pharmacy

Compounds for one identified patient from a valid prescription. Licensed and inspected day to day by the state board of pharmacy.

503B outsourcing facility

Registers with the FDA, follows federal manufacturing rules, is inspected by the FDA, and may compound batches for clinics without patient-specific prescriptions.

FDA approval

Neither. Compounded drugs are not FDA-approved and are not reviewed before dispensing.

Which fills PeRx prescriptions

State-licensed 503A pharmacies, with every lot tested by an independent laboratory before it ships.

The 503A vs 503B pharmacy question comes down to one sentence. A 503A pharmacy prepares a medication for one patient from a prescription written for that patient, and a 503B outsourcing facility makes larger batches under federal manufacturing standards, mostly for clinics to keep on hand. Compounded medications from either are not FDA approved. That is the whole answer; the rest of this page explains what each half of it means when the medication is a peptide.

The type of compounder behind a peptide prescription is the most useful fact you can know about it and the one most websites skip. PeRx routes every prescription through a state-licensed 503A pharmacy with third-party testing, and this page is the explainer behind that phrase. It sits under our guide to what pharmaceutical-grade peptides means Read nextPharmaceutical Grade Peptides: What It MeansAlmost every peptide seller calls its product "pharmaceutical grade," which is a problem, because the phrase has no legal definition. This guide replaces the marketing word with the concrete, checkable things it should stand for: US-based 503A compounding, USP testing standards, third-party HPLC and mass-spec batch results, and a Certificate of Analysis you can actually request. Then it shows you how to verify each one.Read article , which covers testing and certificates of analysis in depth; this page stays on the two legal pathways.

The one sentence to keep

Compounded is not the same as FDA approved. An approved drug has been reviewed by the agency for safety, effectiveness and manufacturing quality before it is sold. A compounded preparation, from a 503A pharmacy or a 503B facility, has not. What the two pathways provide instead is a licensed preparer, a legal framework for what may be compounded and how, and, under 503A, a prescription written for a named patient.

What Are 503A and 503B?

Both are section numbers in the federal Food, Drug, and Cosmetic Act, the law that gives the FDA its authority over drugs. Section 503A has described traditional pharmacy compounding since 1997. Section 503B was added by the Drug Quality and Security Act, which Congress passed in November 2013 after a 2012 fungal meningitis outbreak: contaminated steroid injections compounded by a single Massachusetts pharmacy caused more than 750 infections and more than 60 deaths across 20 states. The outbreak exposed a gap. A pharmacy was shipping batches nationwide the way a manufacturer would, without a manufacturer's oversight.

The 2013 law created a second category to close it. Compounders that want to make batches for clinics without patient-specific prescriptions can register with the FDA as outsourcing facilities under 503B and accept federal manufacturing rules in exchange. Everyone else stays under 503A, compounding for identified patients under state licensing. The split matters because the two pathways have different oversight and different rules about which ingredients may be used, and peptides sit at the center of the ingredient question. The wider legal picture is in are peptides legal in 2026 Read nextAre Peptides Legal in 2026? Regulatory StatusThe legal landscape for peptides has shifted more in the past two years than in the previous decade. Between FDA reclassifications, compounding pharmacy regulations, and state-level telehealth laws, the status of individual peptides changes frequently. Here is where things stand as of April 2026.Read article .

503A vs 503B Pharmacy: Side by Side

The table compares the two pathways on the points that matter to a patient. The rows come from the FDA's own descriptions of each section, checked on October 21, 2026, and from the United States Pharmacopeia compounding chapters that state boards adopt. Where the law leaves something to the pharmacy, the cell says so; those are the gaps the questions later on this page are built to close.

	503A pharmacy	503B outsourcing facility
Who it serves	One identified patient at a time	Clinics, hospitals and physician offices that keep stock on hand
Prescription required	Yes, for a specific patient, before compounding	No. May compound and ship without a patient-specific prescription, for example for office use
Batch size	Patient-sized, within the limits of prescriptions received	Large batches made ahead of orders
Where the product goes	To the patient named on the prescription	To a clinic shelf or a provider's order
Who oversees it	The state board of pharmacy, day to day; the FDA does surveillance and for-cause inspections	The FDA, which registers the facility and inspects it on a risk-based schedule
Manufacturing standard	USP compounding chapters adopted by the state, including USP <797> for sterile preparations such as injectable peptides	Current good manufacturing practice, the federal factory standard in 21 CFR parts 210 and 211
Testing and environmental monitoring	What USP <797> requires for the pharmacy, plus whatever the pharmacy and its clients add; lot-by-lot release testing is not required by law	Required under current good manufacturing practice, including release testing and environmental monitoring
Which ingredients are allowed	Substances with a USP or NF monograph, components of approved drugs, or substances on the 503A bulks list, each with a certificate of analysis from a manufacturer registered with the FDA	Substances on the separate, shorter 503B bulks list, or on the FDA drug shortage list
Adverse-event reporting	Not a federal requirement; state rules vary	Required, with semiannual product lists filed with the FDA
FDA-approved product	No	No

Who it serves

503A pharmacy: One identified patient at a time
503B outsourcing facility: Clinics, hospitals and physician offices that keep stock on hand

Prescription required

503A pharmacy: Yes, for a specific patient, before compounding
503B outsourcing facility: No. May compound and ship without a patient-specific prescription, for example for office use

Batch size

503A pharmacy: Patient-sized, within the limits of prescriptions received
503B outsourcing facility: Large batches made ahead of orders

Where the product goes

503A pharmacy: To the patient named on the prescription
503B outsourcing facility: To a clinic shelf or a provider's order

Who oversees it

503A pharmacy: The state board of pharmacy, day to day; the FDA does surveillance and for-cause inspections
503B outsourcing facility: The FDA, which registers the facility and inspects it on a risk-based schedule

Manufacturing standard

503A pharmacy: USP compounding chapters adopted by the state, including USP <797> for sterile preparations such as injectable peptides
503B outsourcing facility: Current good manufacturing practice, the federal factory standard in 21 CFR parts 210 and 211

Testing and environmental monitoring

503A pharmacy: What USP <797> requires for the pharmacy, plus whatever the pharmacy and its clients add; lot-by-lot release testing is not required by law
503B outsourcing facility: Required under current good manufacturing practice, including release testing and environmental monitoring

Which ingredients are allowed

503A pharmacy: Substances with a USP or NF monograph, components of approved drugs, or substances on the 503A bulks list, each with a certificate of analysis from a manufacturer registered with the FDA
503B outsourcing facility: Substances on the separate, shorter 503B bulks list, or on the FDA drug shortage list

Adverse-event reporting

503A pharmacy: Not a federal requirement; state rules vary
503B outsourcing facility: Required, with semiannual product lists filed with the FDA

FDA-approved product

503A pharmacy: No
503B outsourcing facility: No

One reading of the table: "more federal oversight" does not mean "better for you." 503B exists so that a clinic can stock a drug; a facility making thousands of vials for clinic shelves is solving a different problem than a pharmacy making one vial for you. The rows that most affect a peptide patient are the ingredient row and the testing row, which is where the rest of this page goes.

How PeRx Sources: A State-Licensed 503A Pharmacy With Third-Party Testing

PeRx is a telehealth platform, not a pharmacy, so the honest way to describe our sourcing is to describe the pathway every prescription goes through. A licensed provider reviews your health history and writes a prescription in your name. A state-licensed 503A pharmacy in our network compounds it under USP <797> sterile standards, from active ingredients that arrive with a certificate of analysis from a manufacturer registered with the FDA. Before the lot is released, an independent laboratory, not the pharmacy that made it, tests it for potency, sterility, endotoxins and pH. The vial then ships overnight in temperature-controlled packaging, fully reconstituted and ready to use, with the concentration on the label and your prescribed dose on paper with it.

What the third-party testing covers

Potency by HPLC (USP <621>), sterility by membrane filtration (USP <71>), bacterial endotoxins by LAL assay (USP <85>) and pH (USP <791>), on every lot, before release. The certificate of analysis for your lot is available on request, and the quality testing page shows a sample certificate and lists each test and why it is run. None of this makes a compounded peptide an FDA-approved drug; it makes the vial checkable.

What Is a 503A Pharmacy?

A 503A pharmacy is a compounding pharmacy that meets the conditions in section 503A. In exchange, its preparations are exempt from three requirements that apply to manufacturers: premarket approval, current good manufacturing practice, and the labeling rules for directions of use. The conditions, in short sentences: a licensed pharmacist in a state-licensed pharmacy, or a licensed physician, compounds it for an identified patient from a valid prescription, after the prescription is received. It is prepared under the state board's rules and the USP chapters the state adopts, which for an injectable means USP <797>. Any bulk ingredient must have a USP or NF monograph, be a component of an approved drug, or appear on the FDA's 503A bulks list, with a valid certificate of analysis from a manufacturer registered with the FDA. And the pharmacy may not compound copies of commercially available drugs, or drugs withdrawn for safety reasons.

The certificate-of-analysis rule is the quiet hero of the section. It means the raw peptide entering a 503A pharmacy already carries documented identity and purity from a manufacturer the FDA can identify, which is more than any research-chemical vendor is obliged to provide. Reading one is a skill worth having; how to read a peptide COA Read nextHow to Read a Peptide COAA Certificate of Analysis is the lab report behind a peptide vial. Learn to read one line by line: identity, purity, net peptide content, sterility, and endotoxin. Then learn the red flags that separate a real prescription COA from the screenshot a gray-market vendor pastes into a product page.Read article walks through it line by line.

What Is a 503B Outsourcing Facility?

An outsourcing facility is a compounder that has chosen to register with the FDA under section 503B, a voluntary category created by the 2013 law. Registration brings obligations a 503A pharmacy does not have: compliance with current good manufacturing practice, inspection by the FDA on a risk-based schedule, reporting of adverse events, and a list of every product compounded, filed with the agency in June and December. In return, the facility may compound and distribute without patient-specific prescriptions, which is what lets a clinic order a batch for office use. "Outsourcing facility" is the legal term; in practice it is closer to a small manufacturer than to the pharmacy on the corner, and its products are still not FDA-approved drugs.

What This Means for the Peptides You Are Prescribed

Is compounded the same as FDA approved? No. A compounded medication is not FDA approved, and the FDA does not review it for safety and effectiveness before it is made, whether the compounder is a 503A pharmacy or a 503B facility. What a prescription and a licensed pharmacy add is a clinician who decided the medication was appropriate for you, a preparer who is licensed and inspected, documented ingredients, and a legal record of what you were given. That is a different thing from a research-chemical vial with nobody accountable for it, and it is also a different thing from an approved drug. Keeping those three categories apart is most of the work of being an informed patient.

Peptides make the ingredient rules the live issue. Most peptides are not FDA-approved drugs and have no USP monograph, so a compounding pharmacy peptides program depends on a lawful basis for each substance, usually a place on the FDA's 503A bulks list or a nomination moving through the agency's review. In 2026 that review moved: in April the FDA removed a dozen peptides from its Category 2 list, the group it had flagged for safety concerns, and on July 23 and 24 its Pharmacy Compounding Advisory Committee reviewed seven of them, including BPC-157 Explore PeRxBPC-157The Body Protection CompoundView peptide , TB-500 and KPV. A committee recommendation is advice to the agency, not an approval, and adding a substance to the bulks list takes formal rulemaking that can run a year or more. The detail lives in our July 2026 FDA peptide review Read nextJuly 2026 FDA Peptide Panel: BPC-157 ReviewOn July 23-24, the FDA's Pharmacy Compounding Advisory Committee will review seven peptides, including BPC-157, TB-500, and Semax. Despite the headlines, this is not a ban, and these peptides are not suddenly "legal again" either. Here is the precise, physician-reviewed picture of where things actually stand and what it means if you use peptide therapy.Read article coverage, the explainer on whether the FDA will ban peptides Read nextWill the FDA Ban Peptides in 2026? What the Data SaysSearch "FDA peptide ban" and you will find panic in one direction and "they're legal again!" in the other. Both are wrong. Here is the precise, physician-reviewed answer to whether the FDA is banning peptides in 2026, and what the actual regulatory record shows.Read article , and the list of FDA-approved peptides Read nextFDA-Approved Peptides: The Full List (2026)Peptide drugs have been FDA-approved for over forty years, from recombinant insulin in 1982 to tirzepatide in 2022. Most of the peptides people actually search for, though, are not on that list. This guide lays out every FDA-approved peptide drug with its brand names and approval year, explains the difference between an approved drug, a compounded medication, and a research chemical, and covers where the 2026 FDA compounding review left peptides like BPC-157. Current as of August 2026.Read article . A 503A pharmacy compounds a peptide only when the pharmacist can point to the basis for doing so, and a good one will tell you what it is; research peptides vs prescription peptides Read nextResearch Peptides vs Prescription Peptides (2026)An honest comparison for the patient who already uses peptides, what the 'Not for Human Use' label actually means, the real quality differences, and the practical steps to switch from research-chemical sourcing to a prescription supply.Read article covers the vials that skip all of this.

What to Ask Your Provider

Six questions settle most of what matters about a peptide pharmacy, and a provider who cannot answer them is telling you something. Is the pharmacy state-licensed, and is it a 503A pharmacy or a 503B outsourcing facility? Who is the responsible pharmacist, and in which state? Is there a certificate of analysis for the ingredient, and a third-party test of the finished product? Is this peptide lawfully compounded, and on what basis? How is the vial stored and shipped, and does it arrive ready to use? And who follows up with me at renewal and if something goes wrong?

The longer version, with the reasons behind each question, is the provider checklist. How to choose a telehealth peptide provider Read nextHow to Choose a Telehealth Peptide ProviderThe peptide space is full of operators who look clinical and are anything but. A slick site and a checkout button tell you nothing about who reviewed your health history, where the vial was made, or whether anyone tested what is inside it. This is the honest buyer's checklist: the green flags that mean a provider is real, the red flags that should end the conversation, and how to tell them apart before you hand over a card.Read article applies it to online clinics, and is it safe to buy peptides online Read nextIs It Safe to Buy Peptides Online?The honest answer is that it depends entirely on the source. "Buying peptides online" covers two opposite things: unregulated research-chemical websites, and licensed telehealth backed by a real provider and an FDA-regulated pharmacy. One of those is safe. This guide shows you how to tell them apart.Read article covers the sellers that fail it.

Getting Peptides Prescribed Through PeRx

The path is short, and the 503A vs 503B pharmacy question is already answered for you. You complete an eligibility check, a licensed provider reviews your health history and goals, and if a prescription is written, a state-licensed 503A pharmacy in our network compounds it and ships it ready to use. There is no separate consultation fee. Compounded peptides are not FDA-approved drugs, and PeRx does not sell research-use products. The full peptide catalog shows what a provider can prescribe, and the compare pages put the common options side by side.

Want to know which peptide a provider would consider for you?

New to PeRx: the eligibility check takes about a minute, and a licensed provider reviews every order before a pharmacy fills it. Already a patient: message your care team with questions about your prescription or your pharmacy.

Check eligibility Message your care team

503A vs 503B Pharmacy FAQs

No. Compounded drugs are not FDA-approved, and the FDA does not review a compounded preparation for safety, effectiveness or quality before it is dispensed. A prescription from a licensed pharmacy adds a clinician, a licensed preparer and documented ingredients. It does not add FDA approval.

Not as a rule. A 503B facility follows federal manufacturing standards and is inspected by the FDA, but it makes batches for clinics, not a vial for you, and it may compound fewer substances. A 503A pharmacy compounds from your prescription under state licensing, and independent lot testing can close the testing gap.

No. A 503A pharmacy may use a bulk substance only if it has a USP monograph, is a component of an approved drug, or is on the FDA's 503A bulks list, and it must come with a certificate of analysis. Most peptides fall outside the first two, so the lawful basis depends on the FDA's list and its ongoing review.

Yes, from a 503A pharmacy. Section 503A requires a valid prescription for an identified patient before the medication is compounded. A 503B facility may compound without a patient-specific prescription, but it ships to clinics and providers, not to you directly.

Ask the provider, then check the label. The dispensing pharmacy's name, address and license state should be on the vial or the packaging, and the state board of pharmacy publishes license status online. A provider who will not name the pharmacy has not answered the question.

It is a licensed pharmacy that also compounds. Many community pharmacies compound occasionally; dedicated compounding pharmacies do little else. Both work under section 503A and the state board of pharmacy, and both must follow USP chapters, including USP <797> for sterile preparations.

Sometimes. The state board of pharmacy has day-to-day responsibility, and the FDA conducts surveillance and for-cause inspections of 503A compounders when it has reason to. Outsourcing facilities under 503B are inspected by the FDA on a risk-based schedule as a condition of registration.

Related Guides

Continue reading about peptides and protocols that pair well with this guide.

How to Get Peptides Prescribed Online

There is a legitimate way to get peptides prescribed through telehealth, and there is a gray market that skips the medicine entirely. This guide walks the real path step by step: the online assessment, the licensed provider who reviews it, the US compounding pharmacy that prepares your peptide, and the box that arrives ready to use. It also shows you how to spot the sites you should walk away from.

11 min readRead

Nausea & Gut Issues on GLP-1s: What Helps

GI side effects are the single biggest reason patients stop Ozempic, Wegovy, and Mounjaro. Here is why GLP-1 receptor activation hits the gut so hard, which simple changes resolve most cases, and which peptide helps when the basics have not been enough.

9 min readRead

Is Thymosin Alpha-1 FDA Approved? Not in the US

Not in the United States. But Thymosin Alpha-1 is approved for medical use in over 35 countries under the brand name Zadaxin, primarily for hepatitis B and C treatment and as an immune system modulator. It has FDA Orphan Drug designation for hepatocellular carcinoma. It is one of the most clinically validated peptides in existence, everywhere except the US.

6 min readRead

References and Review

Every regulatory statement on this page was checked against the FDA pages below on October 21, 2026, using the "content current as of" date each page carries. The 2026 peptide-specific actions are documented, with their own sources, in the linked FDA coverage. No pharmacy is named on this page.

U.S. Food and Drug Administration. Human Drug Compounding (overview): compounding defined; compounded drugs are not FDA approved. Content current as of June 15, 2026. View study

U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. State-board oversight of 503A compounders; 503B registration, CGMP and risk-based FDA inspection. Content current as of September 16, 2025. View study

U.S. Food and Drug Administration. Human Drug Compounding Laws. The Drug Quality and Security Act of November 27, 2013 and the 2012 outbreak behind it; sections 503A and 503B. Content current as of December 17, 2024. View study

U.S. Food and Drug Administration. Information for Outsourcing Facilities: registration, CGMP, risk-based inspection, adverse event reporting and semiannual product lists. Content current as of March 29, 2022. View study

U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act: the three lawful bases, certificate of analysis, registered manufacturer, Categories 1 to 3. Content current as of May 14, 2026. View study

United States Pharmacopeia. General Chapter <797> Pharmaceutical Compounding: Sterile Preparations, and General Chapter <795> Pharmaceutical Compounding: Nonsterile Preparations (revised chapters official November 1, 2023). View study

Medical Disclaimer

The information provided on this website, including all articles, guides, and educational content, is for informational and educational purposes only and is not intended as medical advice, diagnosis, or treatment. Nothing on this site should be construed as a substitute for professional medical advice from a qualified healthcare provider.

The majority of peptides discussed on this site are not approved by the U.S. Food and Drug Administration (FDA) for the indications described. They are classified as bulk drug substances and are available only through a licensed prescribing provider and compounding pharmacy. All treatments require a valid prescription and provider oversight.

The majority of published research on peptide therapies has been conducted in preclinical (animal) models. While early human data is encouraging, comprehensive clinical trial data remains limited for most peptide compounds. Individual results may vary significantly based on health status, injury type, and other factors. No specific outcomes are guaranteed.

Certain peptides discussed on this site are classified as prohibited substances by the World Anti-Doping Agency (WADA) and are banned by major sports organizations including the NFL, NCAA, UFC, NBA, MLB, NHL, and PGA. If you are subject to anti-doping testing, consult your governing body before considering any peptide therapy.

Statements on this website have not been evaluated by the Food and Drug Administration. Products and therapies discussed are not intended to diagnose, treat, cure, or prevent any disease.